…stents (BMS) in response to restenosis caused principally by neointimal hyperplasia. Contemporary DES combine a metallic scaffold, a polymeric or polymer free drug delivery system…

… stent related risk; whether long term oral anticoagulation is required; tolerance of treatment during the initial months. Patients with HBR are the principal candidates for…

…used in two principal settings: After ACS , whether managed medically or with revascularization. After elective PCI for CCS , particularly after stent implantation. In both situations…

…to provide similar efficacy to higher doses while reducing bleeding risk. Low dose aspirin is also preferred in patients with intracoronary stents. In acute ACS…

…myocarditis) or non cardiac conditions (such as renal failure). To establish a diagnosis of MI, acute myocardial injury must be coupled with clinical evidence of…

…Non ischaemic myocardial injury may accompany numerous cardiac and systemic disorders, including: Cardiac causes Systemic causes Heart failure Sepsis Myocarditis Chronic kidney disease Cardiomyopathy Stroke…

…presenting with acute coronary syndrome (ACS) and confirmed by angiography or pathology. The Academic Research Consortium framework additionally distinguishes definite, probable, and possible stent thrombosis…

…through intimal thickening. DES release antiproliferative and anti inflammatory agents from the stent surface and have substantially reduced this process compared with BMS. Neoatherosclerosis Neoatherosclerosis…

…MI: MI related to PCI. Type 4b MI: MI caused by stent thrombosis. Type 4c MI: MI associated with in stent restenosis. Type 5 MI:…

…the system, compared with roughly 70–200 µm for gray scale IVUS. This allows detailed visualization of the lumen surface, fibrous cap thickness, thrombus, stent…